Hyperfine (NASDAQ:HYPR) vs. Avanos Medical (NYSE:AVNS) Head to Head Survey

Hyperfine (NASDAQ:HYPR – Get Free Report) and Avanos Medical (NYSE:AVNS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Risk and Volatility

Hyperfine has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Profitability

This table compares Hyperfine and Avanos Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hyperfine -156.42% -91.18% -55.49%
Avanos Medical -10.39% 5.39% 3.97%

Institutional & Insider Ownership

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 95.2% of Avanos Medical shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 2.3% of Avanos Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Hyperfine and Avanos Medical”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hyperfine $11.40 million 5.23 -$35.57 million ($0.30) -1.87
Avanos Medical $715.90 million 1.64 -$72.90 million ($1.61) -15.52

Hyperfine has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Hyperfine and Avanos Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine 1 1 3 1 2.67
Avanos Medical 1 1 0 0 1.50

Hyperfine currently has a consensus target price of $2.02, indicating a potential upside of 260.58%. Given Hyperfine’s stronger consensus rating and higher probable upside, research analysts clearly believe Hyperfine is more favorable than Avanos Medical.

Summary

Hyperfine beats Avanos Medical on 9 of the 15 factors compared between the two stocks.

About Hyperfine

(Get Free Report)

Hyperfine, Inc. develops portable magnetic resonance imaging (MRI) technology for brain imaging. Its Swoop system is a low-field MRI scanner designed to bring imaging to patients at the point of care, including settings where access to conventional MRI equipment may be limited. The Swoop system is designed for use near a patient’s bedside and does not require a dedicated MRI suite. The U.S. Food and Drug Administration cleared the system in 2020, marking a milestone for the use of portable MRI in clinical care.

About Avanos Medical

(Get Free Report)

Avanos Medical, Inc. develops and markets medical devices and related products, with a focus on digestive health and pain management. Its offerings include enteral feeding tubes and delivery systems, as well as devices used in regional anesthesia and non-opioid pain management. The company’s products are used in hospitals, other health care facilities and home-care settings. Avanos serves customers in the United States and internationally. Avanos traces its history to Halyard Health, which became an independent company after separating from Kimberly-Clark in 2014.

Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.